A neuro-oncologist's perspective on adjuvant radiosurgery for patients with newly diagnosed brain metastases

Expert Review of Neurotherapeutics

Volumn 5, Issue 4, 2005, Pages 429-431

  Chamberlain, Marc C ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM TEXAPHYRIN;

BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; DEMENTIA; EDITORIAL; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; NEUROLOGIC DISEASE; PARENCHYMA; QUALITY OF LIFE; RADIATION INJURY; TREATMENT OUTCOME;

BRAIN NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; PHYSICIAN'S ROLE; RADIOSURGERY; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 22544438426     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.4.429     Document Type: Editorial

References (7)

1. Lo SS, Chang EL, Suh J. Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases. Expert Rev. Neurotherapeutics 5(4), 487-495 (2005).
2. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17), 1485-1489 (1998). Established the role of whole-brain radiotherapy in addition to aggressive local therapy for single brain metastases.
3. DeAngelis LM, Mandell LR, Thaler HT et al. The role of postoperative radiotherapy after resection of single brain metastases. Neurosurg. 24, 798-805 (1989).
4. Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized Phase III trial. J Clin. Oncol. 22(1), 157-165 (2004).
5. Andrews DW, Scott CB, Sperduto PW et al. Whole-brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet. 363(9422), 1665-1672 (2004). Established the role of a stereotactic radiosurgery boost after whole-brain radiotherapy for selected patients with one to three brain metastases.
6. Mañon R, Oneill A, Mehta M et al. Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397). J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post Meeting Edition). 22, 14S, (Abstract).
7. Aoyama H. ASCO Annual Meeting Proceedings (Post Meeting Edition). J. Clin. Oncol. 22, 18S(Abstract) (2004).